logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Avelumab in addition to best supportive care for locally advanced or metastatic urothelial cancer

< Back

Avelumab in addition to best supportive care for locally advanced or metastatic urothelial cancer

Drugs

Cancer and Palliative Care

November 2019


Avelumab in addition to best supportive care (BSC) is in clinical development for the maintenance treatments of adults with locally advanced or metastatic urothelial cancer that did not progress on or following completion of first-line chemotherapy. Urothelial cancer occurs on the lining of the bladder and other parts of the urinary system. In advanced urothelial cancer, cancer has grown into deeper layers including connective tissue or muscle. Metastatic urothelial cancer is when the cancer has spread to other parts of the body, such as the liver or bones. Urothelial cancer usually occurs in patients aged 60 years and older, where patients may have other medical conditions or are not fit enough to be given certain treatments.
Avelumab administered by intravenous infusion is designed to stimulate the body’s own immune system to fight cancer cells. If licensed, avelumab in addition to BSC will offer a maintenance treatment option for patients with locally advanced or metastatic urothelial cancer that did not progress during or following completion of first-line chemotherapy.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts